Accelerating CMC development is essential to meet the demand for rapid clinical entry of biologics. Conventional processes are limited by long cell line and upstream development cycles. In this presentation, we will introduce ProBio’s new Express CMCTM service, which delivers toxicology batch materials within 4 months from a single clone, and highlight the technology enablers that drive faster development timeline without compromising.
Ying Li, Director of Antibody PD Department, ProBio